Previous Article | Next Article ![]()
Infection and Immunity, December 2002, p. 6567-6575, Vol. 70, No. 12
0019-9567/02/$04.00+0 DOI: 10.1128/IAI.70.12.6567-6575.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Departments of Pathology and Laboratory Medicine,1 Molecular Biology Institute, University of California, Los Angeles, California 90095,2 Santarus, Inc., San Diego, California 921303
Received 1 May 2002/ Returned for modification 2 July 2002/ Accepted 21 August 2002
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The identity of colitigenic bacterial species remains uncertain. In humans, a variety of bacterial and viral species have been implicated in CD, mainly on the basis of seroreactivity (3, 5, 8, 28, 44). However, CD patients typically express elevated levels of antibodies to many bacterial proteins, perhaps due to mucosal disruption and local immunologic challenge by diverse intestinal microflora. Mycobacterium has received attention as a candidate human pathogen, based on serologic evidence, but the presence of mycobacterial DNA in lesions is controversial (9, 12, 31, 32, 43, 47). Bacteroides vulgatus and Helicobacter hepaticus have been evaluated with various rodent IBD models, but other intestinal commensal organisms yet undefined are likely to account for the major colitigenic species (14, 25, 35, 36).
Our laboratory recently introduced subtractive cloning as a fresh approach to identify candidate organisms in human CD (10, 45). A novel microbial gene, I2, was isolated from lesional versus adjacent uninvolved colon tissues of a patient with CD. In a population-based study (45), the I2 gene was selectively detected in lesional CD colonic tissue, although it was also prevalent in both healthy and CD ileum. In that study, antibodies reactive with the recombinantly expressed protein also were detected in CD patients. The recombinant I2 protein also was found to be a murine CD4 T-cell superantigen (11). These lines of evidence suggest that the I2 protein and its originating bacterium might play roles in the pathogenesis of CD. The present study addresses the identity of the originating bacterium and the genomic locus bearing the I2 gene segment.
| MATERIALS AND METHODS |
|---|
|
|
|---|
|
Sequence analysis. Plasmid clones were sequenced by dideoxy chain termination, assembled with the University of Wisconsin Genetics Computer Group (GCG) programs and the BLAST program (version 20.11, 20 January 2000), as well as the National Center for Biotechnology Information nonredundant database (2). Amino acid sequence alignment was performed with the ClustalW program at the EMBL Outstation European Bioinformatics Institute and with the GenDoc program (www.psc.edu/biomed/genedoc).
Cloning full-length pfiT and its adjacent genes. Genome-walking (rapid amplification of cDNA ends [RACE] cloning) was employed to clone full-length pfiT gene from P. fluorescens genome (Universal GenomeWalker kit; Clontech, Palo Alto, Calif.). Reverse and forward GSP oligonucleotide pairs were designed to obtain upstream and downstream flanking sequences of the primary I2 gene fragment, respectively (Table 2). Genomic DNA of P. fluorescens was amplified on a GeneAmp PCR system 9700 (PE Applied Biosystem) in 50 µl with 1 µg of genomic DNA, 0.5 U of Taq polymerase, 2 mM deoxynucleoside triphosphates (dNTP), and 1 µM primers. Primary PCR was done with 7 cycles of 94°C for 2 s and 70°C for 3 min, followed by 32 cycles of 94°C for 2 s, 65°C for 3 min, and then 65°C for 4 min. Secondary PCR was performed with 5 cycles of 94°C for 2 s and 70°C for 3 min, followed by 20 cycles of 94°C for 2 s, 65°C for 3 min, and 65°C for 4 min. The prevalence of the I2 gene segment of pfiT and a downstream segment in 13 representative Pseudomonas strains was detected by PCR (Table 1). The PCR was performed for 5 min at 95°C, with 30 cycles of 95°C for 60 s, 65°C for 60 s, 72°C for 60 s, and 72°C for 5 min.
|
Expression and purification of recombinant proteins. Recombinant proteins were constructed for the P. aeruginosa homologue (PA2885), pfiT, and the original I2 gene product into pQE-30 (Table 2). E. coli XL-1 Blue transformants were induced (1 mM isopropyl-ß-D-thiogalactopyranoside [IPTG]), and six-His-tagged proteins were purified with a HisTrap column (Amersham) under denatured conditions according to the manufacturer. According to SDS-polyacrylamide gel electrophoresis (PAGE) and gel densitometry, the protein preparations were of similar purities (>85%).
CD4+ T-cell proliferation. Erythrocyte-depleted splenocytes, used as antigen-presenting cells (APCs), were cultured with 1 or 5 µg of antigen per ml at 5 x 106 cells per ml for 12 to 16 h at 37°C and then washed and irradiated at 3,000 rads (567.7 cGy/min for 5.5 min) prior to T-cell coculture. Splenic CD4+ T cells (>85% pure by flow cytometry) were isolated by depletion with nylon wool and anti-B220 and anti-CD8 magnetic beads. CD4+ T cells (4 x 105) were incubated in triplicate with 4 x 105 antigen-pulsed APCs in wells of a 96-well flat-bottom tissue culture plate at 37°C in 5% CO2 humidified air. After 48 h of incubation, 0.5 µCi of [3H]thymidine was added to each culture for the last 18 h of the incubation period, and then the cells were collected with a Micro 96 harvester (Skatron Instruments, Tranby, Norway). Proliferation was assessed with a Betaplate liquid scintillation counter (Wallac, Gaithersburg, Md.).
Detection of P. fluorescens in fecal samples.
Fresh fecal samples from patients with CD were sequentially accrued from the population used in our recent study (10). DNA was isolated with a commercial kit (Stratagene, La Jolla, Calif.), and 0.1 µg was assayed for I2, pfiT, and Omp-W sequences by our previously reported semiquantitative PCR method (10). Doping experiments indicated that the limit of detection for both assays was
2,000 molecules per g of fecal sample. Samples from 30 patients with satisfactory quality were subjected to analysis. In parallel, serial dilutions of fecal samples were cultured on TSA plates at 26°C for conventional microbiologic detection of P. fluorescens. Doping with UCLA 268 indicated a limit of detection of 104 CFU/g of sample.
Nucleotide sequence accession number. The nucleotide sequence data for pfiT and the flanking genomic region in P. fluorescens are available under GenBank accession no. AF173683.
| RESULTS |
|---|
|
|
|---|
|
|
|
The pfiT locus includes an iron-response gene and a genetically unstable element. RACE cloning of pfiT flanking sequence disclosed a previously undefined locus in P. fluorescens. As shown in Fig. 4, P. fluorescens and P. aeruginosa were homologous for several colinear ORFs. Cloning of the region upstream of pfiT reached a hypothetical ORF that was homologous to PA2886, a novel ORF in the same genomic position relative to PA2885 in P. aeruginosa.
|
|
The presence of the novel pfiT downstream region was evaluated with a DNA probe (nucleotide positions 1108 to 2630) in other Pseudomonas species. This region was detected only in P. fluorescens by Southern analysis (Fig. 6). With the pfiT-DF and pfiT-DR primers, a PCR product was detected in UCLA 268, but not in ATCC 13525 or other P. fluorescens clinical isolates (data not shown). These findings indicate that this region is polymorphic among different P. fluorescens isolates.
|
515 kb). This region encoded 459 putative ORFs, with diverse functional categories of these genes, including transcriptional regulators, two-component regulatory systems, small molecule transport, and energy metabolism. Fifty-two percent of the hypothetical proteins in this region lacked definable biological function. In comparison to this region in P. aeruginosa, the features of the pfiT downstream region in the UCLA 268 strain of P. fluorescens (short length, replacement with a novel gene segment, and featured repeat sequence) suggest that it represents a recombination-mediated deletional process (39). CD4+ T-cell activation by PfiT protein homologues. The I2 protein activates murine T cells, displaying features most consistent with a T-cell superantigen (11). We were therefore interested in evaluating whether the full-length parent protein (PfiT) or its P. aeruginosa homologue (PA2885) was also immunostimulatory. In the previous report, recombinant proteins were expressed as glutathione S-transferase (GST) fusion proteins. In this study, a His-tagged protein expression vector was used to express I2, PfiT, and PA2885, and the recombinant proteins were purified by nickel chromatography. The proteins were preincubated with APCs and tested for their ability to stimulate CD4+ T-cell proliferation (Fig. 7). Both I2 and PfiT strongly stimulated proliferation, at levels similar to each other and to that of the superantigen control (SEB). In contrast, PA2885 stimulated a weaker response. This difference was not due detectable differences in protein purity. First, the proteins were of similar purities by SDS-PAGE criteria. Second, experiments combining I2 (1 or 5 µg/ml) with PA2885 (0.5, 1, and 2.5 µg/ml) revealed the same or additive proliferation compared to experiments with I2 alone. Thus, there did not appear to be an inhibitor in the PA2885 preparation for I2-induced CD4+ T-cell stimulation (data not shown). These results indicated that PfiT induces CD4+ T-cell proliferation and that the central third of the PfiT protein (I2) is the functional domain for this bioactivity. Sequence polymorphisms between PfiT and PA2885 may be structurally important for CD4+ T-cell stimulation.
|
| DISCUSSION |
|---|
|
|
|---|
I2, PfiT, and P. fluorescens. Several lines of evidence indicate the I2 is derived from the pfiT gene of P. fluorescens. Southern and PCR analyses of 13 bacterial species in the family Pseudomonadaceae demonstrated that the I2 sequence was present in P. fluorescens alone. Molecular cloning of this genomic region from a clinical isolate of P. fluorescens disclosed a new gene, pfiT, which was detected in all of the 14 P. fluorescens isolates available for examination. The physiologic role of PfiT and its P. aeruginosa homologue (PA2885) is unknown. On structural grounds, they are predicted to be a tetR-like component of transcription complexes (42, 45).
Analysis of the genomic region surrounding pfiT in P. fluorescens revealed overall homology with the corresponding region of P. aeruginosa with respect to both the organization and complement of predicted ORFs. One of these adjacent genes was pbrA, an iron-responsive gene of P. fluorescens, with homologues pvdS and pfrI in P. aeruginosa and Pseudomonas putida, respectively (26, 41, 49). PbrA protein upregulates certain siderophores and exotoxins facilitating the iron deprivation response, and in some systems, it is an important virulence factor (50).
I2 was recently shown in murine assays to be a new structural class of T-cell superantigen, activating CD4+ T cells particularly by using the T-cell receptor (TCR) Vß5 gene (11). In this study, PfiT was also found to activate CD4+ T cells, with a potency comparable to that of the I2 protein. This indicates that the central region of PfiT (the I2 sequence) fully accounts for the immunologic activity of the protein. Compared to PfiT, PA2885 was only modestly stimulatory, suggesting that PA2885 may differ in sequences affecting the avidity of major histocompatibility complex (MHC) or TCR binding.
T-cell superantigens are an important virulence trait of certain pathogenic bacteria, due to direct and indirect tissue damage mediated by the cognately activated T-cell population (27, 30). Among species known to express T-cell superantigens, gram-negative bacteria are notably absent, with the exception of an apparent T-cell superantigen in Yersinia pseudotuberculosis (1). PfiT is thus distinguished both as a distinct structural class of T-cell superantigens and as the first example of such bioactivity in gram-negative intestinal commensals. The modest immunoactivity of PA2885 makes it uncertain whether P. aeruginosa may express significant T-cell superantigen activity. In view of the important pathogenicity of P. aeruginosa in several clinical settings, the issue of PA2885 immunoactivity may deserve further study.
Members of the family Pseudomonadaceae are rare components of fecal bacteria of the colon, usually below the limits of culture detection (16, 48). There are reports associating fecal Pseudomonadaceae with CD (17, 18), but the findings are inconsistent (3, 20, 33). Similarly, the present study did not detect fecal P. fluorescens in CD patients, but the limits of detection were 10,000 CFU or 2,000 gene copies per g of stool, respectively, for culture or PCR assay. However, a PCR assay for the P. fluorescens-specific I2 sequence is usually positive for mucosa of the ileum (healthy as well as with IBD) and colon (CD) (45). This suggests that P. fluorescens may be a normal, low-level commensal of ileal mucosa and may broaden its colonization to susceptible colonic mucosa in CD.
Swidsinski et al. recently reported a striking elevation of colonic mucosa-associated bacteria of diverse genera in IBD, suggesting that IBD may involve a disorder in the regulation of bacterial-mucosal adherence (46). That study did not detect Pseudomonas in their culture assay (perhaps due to the limit of detection) and observed the disordered adherence found in both ulcerative colitis and CD. However, it points to the idea that disordered mucosal adherence in CD may be a predisposing factor for the association of mucosal P. fluorescens in CD. Colonization by P. aeruginosa and its pathogenicity of P. aeruginosa are opportunistic, with dependence on local host factors and microbial traits modifying host-bacterial interaction (15, 23, 42). In mouse experimental and genetic models, diverse modes of immunologic or structural disturbance of the intestinal mucosa promote a CD-like disease (6, 7). While P. fluorescens rarely involves opportunistic infection (22), the disordered mucosal environment in genetically susceptible individuals may suit P. fluorescens opportunism and through expression of the PfiT superantigen may contribute a role in CD mucosal damage.
| ACKNOWLEDGMENTS |
|---|
This work was supported by NIH DK46763 (J.B.), the Jonsson Comprehensive Cancer Center (J.B.), and the Crohn's and Colitis Foundation of America (W.B.).
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Abe, J., M. Onimaru, S. Matsumoto, S. Noma, K. Baba, Y. Ito, T. Kohsaka, and T. Takeda. 1997. Clinical role for a superantigen in Yersinia pseudotuberculosis infection. J. Clin. Investig. 99:1823-1830.[Medline] |
| 2. | Altschul, S. F., W. Gish, W. Miller, E. W. Meyers, and D. J. Lippman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410.[CrossRef][Medline] |
| 3. | Auer, I. O., A. Roder, F. Wensinck, J. P. van de Merwe, and H. Schmidt. 1983. Selected bacterial antibodies in Crohn's disease and ulcerative colitis. Scand. J. Gastroenterol. 18:217-223.[Medline] |
| 4. | Bhan, A. K., E. Mizoguchi, R. N. Smith, and A. Mizoguchi. 1999. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol. Rev. 169:195-207.[CrossRef][Medline] |
| 5. | Blaser, M. J., R. A. Miller, J. Lacher, and J. W. Singleton. 1984. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 87:888-894.[Medline] |
| 6. | Blumberg, R. S., L. J. Saubermann, and W. Strober. 1999. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr. Opin. Immunol. 11:648-656.[CrossRef][Medline] |
| 7. | Bregenholt, S., D. Delbro, and M. H. Claesson. 1997. T-cell transfer and cytokine TCR gene deletion models in the study of inflammatory bowel disease. APMIS 105:655-662.[Medline] |
| 8. | Cohavy, O., D. Bruckner, L. K. Gordon, R. Misra, B. Wei, M. E. Eggena, S. R. Targan, and J. Braun. 2000. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect. Immun. 68:1542-1548. |
| 9. | Cohavy, O., G. Harth, M. Horwitz, M. Eggena, C. Landers, C. Sutton, S. R. Targan, and J. Braun. 1999. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect. Immun. 67:6510-6517. |
| 10. | Dalwadi, H., B. Wei, and J. Braun. 2000. Defining new pathogens and non-culturable infectious agents: the case of inflammatory bowel disease. Curr. Opin. Gastroenterol. 16:56-59. |
| 11. | Dalwadi, H., B. Wei, M. Kronenberg, C. L. Sutton, and J. Braun. 2001. The Crohn's disease-associated bacterial protein I2 is a novel enteric T cell superantigen. Immunity 15:149-158.[CrossRef][Medline] |
| 12. | Del Prete, R., M. Quaranta, A. Lippolis, V. Giannuzzi, A. Mosca, E. Jirillo, and G. Miragliotta. 1998. Detection of Mycobacterium paratuberculosis in stool samples of patients with inflammatory bowel disease by IS900-based PCR and colorimetric detection of amplified DNA. J. Microbiol. Methods 33:105-114.[CrossRef] |
| 13. | De Winter, H., H. Cheroutre, and M. Kronenberg. 1999. Mucosal immunity and inflammation. II. The yin and yang of T cells in intestinal inflammation: pathogenic and protective roles in a mouse colitis model. Am. J. Physiol. 276:G1317-G1321. |
| 14. | Dieleman, L. A., A. Arends, S. L. Tonkonogy, M. S. Goerres, D. W. Craft, W. Grenther, R. K. Sellon, E. Balish, and R. B. Sartor. 2000. Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10-deficient mice. Infect. Immun. 68:5107-5113. |
| 15. | Epelman, S., T. F. Bruno, G. G. Neely, D. E. Woods, and C. H. Mody. 2000. Pseudomonas aeruginosa exoenzyme S induces transcriptional expression of proinflammatory cytokines and chemokines. Infect. Immun. 68:4811-4814. |
| 16. | Finegold, S. M., V. L. Sutter, P. T. Sugihara, H. A. Elder, S. M. Lehmann, and R. L. Phillips. 1977. Fecal microbial flora in Seventh Day Adventist populations and control subjects. Am. J. Clin. Nutr. 1:1781-1792. |
| 17. | Foreman, N. K., W. C. Wang, E. J. Cullen, G. L. Stidham, T. A. Pearson, and J. L. Shenep. 1991. Endotoxic shock after transfusion of contaminated red blood cells in a child with sickle cell disease. Pediatr. Infect. Dis. J. 10:624-626.[Medline] |
| 18. | Franzetti, F., M. Cernuschi, R. Esposito, and M. Moroni. 1992. Pseudomonas infections in patients with AIDS and AIDS-related complex. J. Intern. Med. 231:437-443.[Medline] |
| 19. | Garcia-Lafuente, A., M. Antolin, F. Guarner, E. Crespo, A. Salas, P. Forcada, and J. Malagelada. 1998. Derangement of mucosal barrier function by bacteria colonizing the rat colonic mucosa. Eur. J. Clin. Investig. 28:1019-1026.[CrossRef][Medline] |
| 20. | Graham, D. Y., H. H. Yoshimura, and M. K. Estes. 1983. DNA hybridization studies of the association of Pseudomonas maltophilia with inflammatory bowel diseases. J. Lab. Clin. Med. 101:940-954.[Medline] |
| 21. | Gui, G. P. H., P. R. S. Thomas, M. L. V. Tizard, J. Lake, J. D. Sanderson, and J. Hermon-Taylor. 1997. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J. Antimicrob. Chemother. 39:393-400. |
| 22. | Hsueh, P.-R., L.-J. Teng, H.-J. Pan, Y.-C. Chen, C.-C. Sun, S.-W. Ho, and K.-T. Luh. 1998. Outbreak of Pseudomonas fluorescens bacteremia among oncology patients. J. Clin. Microbiol. 36:2914-2917. |
| 23. | Ichikawa, J. K., A. Norris, M. G. Bangera, G. K. Geiss, A. B. Wout, R. E. Bumgarner, and S. Lory. 2000. Interaction of Pseudomonas aeruginosa with epithelial cells: identification of differentially regulated genes by expression microarray analysis of human cDNAs. Proc. Natl. Acad. Sci. USA 97:9659-9664. |
| 24. | Janowitz, H. D., E. C. Croen, and D. B. Sachar. 1998. The role of the fecal stream in Crohn's disease: an historical and analytic review. Inflamm. Bowel Dis. 4:29-39.[Medline] |
| 25. | Kullberg, M. C., J. M. Ward, P. L. Gorelick, P. Caspar, S. Hieny, A. Cheever, D. Jankovic, and A. Sher. 1998. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect. Immun. 66:5157-5166. |
| 26. | Leoni, L., N. Orsi, V. de Lorenzo, and P. Visca. 2000. Functional analysis of PvdS, an iron starvation sigma factor of Pseudomonas aeruginosa. J. Bacteriol. 182:1481-1491. |
| 27. | Li, H., A. Llera, E. L. Malchiodi, and R. A. Mariuzza. 1999. The structural basis of T cell activation by superantigens. Annu. Rev. Immunol. 17:435-466.[CrossRef][Medline] |
| 28. | Liu, Y., H. J. Van Kruiningen, A. B. West, R. W. Cartun, A. Cortot, and J.-F. Colombel. 1995. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108:1396-1404.[CrossRef][Medline] |
| 29. | Madsen, K. L., J. S. Doyle, M. M. Tavernini, L. D. Jewell, R. P. Rennie, and R. N. Fedorak. 2000. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 118:1094-1105.[CrossRef][Medline] |
| 30. | Marrack, P., and J. Kappler. 1994. Subversion of the immune system by pathogens. Cell 76:323-332.[CrossRef][Medline] |
| 31. | Moss, M. T., E. P. Green, M. L. Tizard, Z. P. Malik, and J. Hermon-Taylor. 1991. Specific detection of Mycobacterium paratuberculosis by DNA hybridisation with a fragment of the insertion element IS900. Gut 32:395-398. |
| 32. | Naser, S. A., K. Hulten, I. Shafran, D. Y. Graham, and F. A. El Zaatari. 2000. Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis. Vet. Microbiol. 77:497-504.[CrossRef][Medline] |
| 33. | Parent, K., and P. Mitchell. 1978. Cell wall-defective variants of Pseudomonas-like (group Va) bacteria in Crohn's disease. Gastroenterology 75:368-372.[Medline] |
| 34. | Prantera, C., F. Zannoni, M. L. Scribano, E. Berto, A. Andreoli, A. Kohn, and C. Luzi. 1996. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am. J. Gastroenterol. 91:328-332.[Medline] |
| 35. | Rath, H. C., H. H. Herfarth, J. S. Ikeda, W. B. Grenther, T. E. Hamm, Jr., E. Balish, J. D. Taurog, R. E. Hammer, K. H. Wilson, and R. B. Sartor. 1996. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J. Clin. Investig. 98:945-953.[Medline] |
| 36. | Rath, H. C., M. Schultz, R. Freitag, L. A. Dieleman, F. Li, H.-J. Linde, J. Schölmerich, and R. B. Sartor. 2001. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun. 69:2277-2285. |
| 37. | Saparov, A., L. A. Kraus, Y. Cong, J. Marwill, X. Y. Xu, C. O. Elson, and C. T. Weaver. 1999. Memory/effector T cells in TCR transgenic mice develop via recognition of enteric antigens by a second, endogenous TCR. Int. Immunol. 11:1253-1264. |
| 38. | Sartor, R. B. 1997. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroenterol. 92:5S-11S.[Medline] |
| 39. | Scott, J. R., and G. G. Churchward. 1995. Conjugative transposition. Annu. Rev. Microbiol. 49:367-397.[CrossRef][Medline] |
| 40. | Sellon, R. K., S. Tonkonogy, M. Schultz, L. A. Dieleman, W. Grenther, E. Balish, D. M. Rennick, and R. B. Sartor. 1998. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 66:5224-5231. |
| 41. | Sexton, R., P. R. Gill, D. N. Dowling, and F. O'Gara. 1996. Transcriptional regulation of the iron-responsive sigma factor gene pbrA. Mol. Gen. Genet. 250:50-58.[Medline] |
| 42. | Stover, C. K., X. Q. Pham, A. L. Erwin, S. D. Mizoguchi, P. Warrener, M. J. Hickey, F. S. Brinkman, W. O. Hufnagle, D. J. Kowalik, M. Lagrou, R. L. Garber, L. Goltry, E. Tolentino, S. Westbrock-Wadman, Y. Yuan, L. L. Brody, S. N. Coulter, K. R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G. K. Wong, Z. Wu, and I. T. Paulsen. 2000. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406:959-964.[CrossRef][Medline] |
| 43. | Suenaga, K., Y. Yokoyama, I. Nishimori, S. Sano, M. Morita, K. Okazaki, and S. Onishi. 1999. Serum antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease. Dig. Dis. Sci. 44:1202-1207.[CrossRef][Medline] |
| 44. | Sutton, C., H.-Y. Yang, J. I. Rotter, S. R. Targan, and J. Braun. 2000. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies (ASCA) in affected and unaffected relatives of Crohn's disease patients. Gut 46:58-63. |
| 45. | Sutton, C. L., J. Kim, A. Yamane, H. Dalwadi, B. Wei, C. Landers, S. R. Targan, and J. Braun. 2000. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 119:23-28.[CrossRef][Medline] |
| 46. | Swidsinski, A., A. Ladhoff, A. Pernthaler, S. Swidsinski, V. Loening-Baucke, M. Ortner, J. Weber, U. Hoffmann, S. Schreiber, M. Dietel, and H. Lochs. 2002. Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44-54.[CrossRef][Medline] |
| 47. | Van Kruiningen, H. J. 1999. Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans. Inflamm. Bowel. Dis. 5:183-191.[Medline] |
| 48. | Wilson, K. H., J. S. Ikeda, and R. B. Blitchington. 1997. Phylogenetic placement of community members of human colonic biota. Clin. Infect. Dis. 25(Suppl. 2):S114-S116. |
| 49. | Wilson, M. J., B. J. McMorran, and I. L. Lamont. 2001. Analysis of promoters recognized by PvdS, an extracytoplasmic-function sigma factor protein from Pseudomonas aeruginosa. J. Bacteriol. 183:2151-2155. |
| 50. | Xiong, Y. Q., M. L. Vasil, Z. Johnson, U. A. Ochsner, and A. S. Bayer. 2000. The oxygen- and iron-dependent sigma factor pvdS of Pseudomonas aeruginosa is an important virulence factor in experimental infective endocarditis. J. Infect. Dis. 181:1020-1026.[CrossRef][Medline] |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|